My Healthcare News & Research — March 3, 2026 · A Shot vs. Daily Doses for Kids With Multiple Food Allergies

At the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting in Philadelphia (February 27 – March 2), National Institutes of Health investigators reported the third and final stage of OUtMATCH — the largest trial yet to compare two very different ways of protecting children allergic to several foods at once. The headline is useful for families: a periodic antibody injection (omalizumab, brand name Xolair) let children fold their trigger foods back into everyday eating about as well as intensive daily oral immunotherapy, with a far lighter routine. Here is what was shown, the numbers, and the caveats that matter before anyone changes a plan.

Table of Contents

  1. 1. What Was Reported
  2. 2. Two Very Different Treatments
  3. 3. The Stage 3 Numbers
  4. 4. What It Means for Families
  5. 5. Honest Caveats
  6. 6. The Takeaway
  7. Key Research Papers
  8. PubMed Topic Searches
  9. Connections
  10. Featured Videos

1. What Was Reported

The study is called OUtMATCH (Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants), a three-stage trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) and carried out by the NIAID-funded Consortium for Food Allergy Research (CoFAR) at ten U.S. clinical sites. It enrolled people aged 1 to 55 who were allergic to peanut and at least two other common foods — milk, egg, wheat, cashew, hazelnut, or walnut. In practice it is overwhelmingly a pediatric trial: the earlier Stage 1 cohort was 177 children and adolescents out of 180 participants. Stage 3 was presented by Robert Wood, MD of Johns Hopkins Children's Center, the trial's lead investigator, and answered the question families care about most: after a year of treatment, can a child put the food on the dinner table and keep eating it — even after the treatment stops?

2. Two Very Different Treatments

Multiple food allergy has no cure. The standard of care is strict avoidance plus carrying epinephrine for accidental exposure and anaphylaxis. Two active strategies now compete to do better than avoidance alone:

Omalizumab (Xolair) is an anti-IgE monoclonal antibody given as an injection every two to four weeks. It mops up the IgE antibodies that drive allergic reactions, raising the amount of a food a person can be exposed to before reacting. In February 2024 it became the first FDA-approved medicine to reduce reactions to one or more foods in patients as young as 1 — an approval built directly on OUtMATCH Stage 1, where 67% of children on omalizumab could tolerate at least 600 mg of peanut protein (roughly two to three peanuts) without a moderate-to-severe reaction, versus just 7% on placebo.

Oral immunotherapy (OIT) takes the opposite approach: the child eats tiny, slowly escalating daily doses of the allergen itself until the body is desensitized. It works, but it is demanding — a daily dose that can itself trigger reactions, plus months of careful up-dosing. Across its three stages, OUtMATCH asked whether the simpler injection could match this more grueling route; Stage 3 is the real-world eating test.

3. The Stage 3 Numbers

Stage 3 followed 80 participants who had completed 52 weeks of treatment — either omalizumab on its own or omalizumab-assisted multi-food OIT — and then tried to integrate one to three of their allergenic foods into a normal diet. Success was defined strictly: eating a meaningful daily portion, at least 300 mg of the food's protein, consistently.

The core finding: at 6 months, more than 60% of participants in both groups were successfully eating the foods, and the two approaches were statistically similar. For peanut specifically, the daily-eating success rate after OIT was 77% and 65% at 3 and 6 months, versus 67% and 60% after omalizumab — close enough that the trial treated them as comparable. Crucially, when participants stopped treatment, the ability to keep eating the foods held up: up to 12 months after stopping, success rates stayed above roughly 60% in both groups.

Safety was similar between the two routes. Among the 52 participants who maintained their dietary plans across all three foods, an adverse event of some kind was reported in 86% of the OIT group and 93% of the omalizumab group — most of them the expected, manageable reactions rather than severe events. In short: two very different treatment burdens landed in nearly the same place.

4. What It Means for Families

Because the two paths end up roughly equivalent, the practical value is choice: a family and their allergist can pick the route that fits the child's life. Omalizumab means no daily allergen dosing and no up-dosing schedule — just an injection every few weeks — appealing for a child juggling several allergies or one who cannot tolerate OIT; its downsides are ongoing injections, a high drug price, and insurance hurdles. OIT has no drug cost and works directly on the specific foods, but it asks the family to give a daily dose of the very allergen, with the reaction risk and time that implies. Both depend on continued exposure to keep working — durable desensitization, not a permanent cure.

5. Honest Caveats

Several limits deserve to be stated plainly, because the headline is easy to over-read:

6. The Takeaway

For a child managing several food allergies at once, 2026 offers two evidence-based routes to more freedom at the table — and OUtMATCH Stage 3 suggests the gentler one, a periodic injection, can get most children about as far as the intensive daily-dosing route, with the benefit holding for up to a year after treatment stops. That is real progress from an era when strict avoidance was the only answer. It is not a cure, it is not risk-free, and it is not a decision to make alone: the next step is a conversation with a pediatric allergist about which path fits your child.

Key Research Papers

  1. Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies (OUtMATCH Stage 1). New England Journal of Medicine. 2024;390(10):889–899. doi:10.1056/NEJMoa2312382 · PMID 38407394
  2. OUtMATCH Stage 3 — dietary integration of allergenic foods after omalizumab versus omalizumab-assisted multi-allergen oral immunotherapy. Presented at the AAAAI 2026 Annual Meeting, Philadelphia, February 27 – March 2, 2026 (Robert Wood, MD, Johns Hopkins Children's Center). Trial registration: ClinicalTrials.gov NCT03881696
  3. Wood RA, et al. Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH). J Allergy Clin Immunol Glob. 2023. PMID 37779534
  4. NIAID/NIH News Release. Antibody reduces allergic reactions to multiple foods in NIH clinical trial. February 25, 2024. nih.gov news release
  5. U.S. Food and Drug Administration. FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure. February 16, 2024. fda.gov press announcement
  6. Recapping AAAAI 2026: updates on food allergy, atopic disease, and asthma. Pharmacy Times. March 2026. pharmacytimes.com

PubMed Topic Searches

  1. PubMed: OUtMATCH omalizumab food allergy
  2. PubMed: omalizumab multiple food allergy children
  3. PubMed: oral immunotherapy peanut allergy children
  4. PubMed: multi-allergen oral immunotherapy desensitization
  5. PubMed: anti-IgE food allergy treatment pediatric
  6. PubMed: food allergy desensitization dietary introduction

Connections

Back to Table of Contents